(Q36173646)

12 August 2017

1 reference

title

Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer (English)

1 reference

12 August 2017

1 reference

Seiji Naito

1

1 reference

12 August 2017

publication date

23 June 2005

1 reference

Japanese Journal of Clinical Oncology

12 August 2017

published in

1 reference

12 August 2017

volume

35

1 reference

12 August 2017

issue

7

1 reference

12 August 2017

page(s)

365-374

1 reference

Natural history of progression after PSA elevation following radical prostatectomy

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

EAU guidelines on prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Management of prostate-specific antigen relapse in prostate cancer: a European Consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Evaluation and management of the man who has failed primary curative therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Biological determinants of cancer progression in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Management of patients with rising prostate-specific antigen after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Markers and meaning of primary treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Transrectal US in evaluation of patients after radical prostatectomy. Part II. Transrectal US and biopsy findings in the presence of residual and early recurrent prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Is there a role for digital rectal examination in the followup of patients after radical prostatectomy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Advances in imaging in the postoperative patient with a rising prostate-specific antigen level

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Noninvasive detection of clinically occult lymph-node metastases in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Evaluation and management of men whose radical prostatectomies failed: results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYI113

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYI113

1 reference

12 August 2017

1 reference